Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The MyHPVscore test represents a successful translation of research from the laboratory to clinical practice. A Michigan ...

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Reducing the dose of radiation to nodal regions is safe and does not impact the risk of recurrence in patients with head and neck cancer, a study suggests.

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

locally advanced head and neck squamous cell carcinoma (HNSCC), according to Phase III clinical trial results presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 ...

Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancer NT219’s mechanism of action ...